Welcome to our dedicated page for Banco Bradesco SEC filings (Ticker: BBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Banco Bradesco S.A. filings document the foreign-issuer disclosures of a Brazilian financial institution whose American depositary shares represent preferred shares. The company furnishes Form 6-K reports covering IFRS consolidated financial statements, management analysis, loan portfolio composition, funding sources, loan-loss provisions, fee income, operating expenses, Basel indicators and economic perspectives.
The filing record also includes disclosures on Bradesco Seguros, digital and customer-service channels, international operations, and healthcare-asset consolidation involving Bradsaúde. Other reports cover CVM/B3 correspondence, material notices to the market, governance matters, controller and director securities transactions, and ownership information relevant to Bradesco's capital structure and ADR investors.
Banco Bradesco gave an update on its plan to consolidate its healthcare businesses into Odontoprev S.A. through a merger of shares and related asset contribution. Management of Bradesco Gestão de Saúde, Odontoprev, Bradesco and Bradseg signed a First Amendment to the merger protocol to include appraisal-report information used to determine Odontoprev’s capital increase, without changing the deal’s terms and conditions.
Following this, an Extraordinary General Shareholders’ Meeting of Odontoprev was convened to approve the merger of BGS into Odontoprev, the resulting capital increase, amendments to Odontoprev’s bylaws including a new corporate name, “Bradsaúde S.A.”, and the asset contribution to Mediservice Operadora de Planos de Saúde S.A.
Banco Bradesco S.A. provides its 2026 corporate and reporting calendar. The bank plans to release quarterly information for 2026 on 05/05/2026 (1st quarter), 07/29/2026 (2nd quarter) and 10/28/2026 (3rd quarter).
The annual shareholders’ meeting materials, including the management proposal and call notice, are scheduled to be sent on 02/06/2026, with the meeting set for 03/10/2026. A videoconference with analysts to discuss 3rd-quarter 2026 results is planned for 10/29/2026. The text also reiterates standard cautionary language about forward-looking statements and related risks and uncertainties.
Banco Bradesco S.A. is calling an extraordinary general meeting for March 31, 2026 to approve the partial spin-off of its wholly owned subsidiary Bradseg Participações S.A., with spun-off net assets of R$ 16,136,310,439.65 being absorbed by Bradesco. The spun-off portion consists of all shares of Bradesco Gestão de Saúde S.A. and Bradseg’s stake in Odontoprev S.A., as the first step in a broader transaction to consolidate Bradesco’s healthcare businesses under Odontoprev. The spin-off will not increase Bradesco’s capital or issue new shares, so there is no shareholder dilution or withdrawal right. Management highlights expected administrative efficiency and a more integrated health and dental offering, with estimated implementation costs around R$ 300,000.00.
Banco Bradesco S.A. called an Extraordinary General Meeting for March 31, 2026 at 4:00 p.m., to be held exclusively in digital format. Shareholders will vote on approving the partial spin-off of Bradseg Participações S.A., with the spun-off net assets absorbed by Bradesco.
This spin-off is part of a broader business combination involving Bradesco Gestão de Saúde S.A. and Odontoprev S.A., with the goal of unifying Bradesco’s health-segment equity interests in Odontoprev. After all stages are completed, Odontoprev is expected to consolidate Bradesco’s healthcare ecosystem, simplifying the corporate structure and potentially improving administrative efficiency.
Banco Bradesco S.A. is restructuring its healthcare businesses by consolidating them under Odontoprev S.A., which will be renamed Bradsaúde S.A.. Bradseg will be partially spun off so that Bradesco directly holds shares of Odontoprev and Bradesco Gestão de Saúde (BGS), and Odontoprev will merge the shares of BGS, making BGS its wholly owned subsidiary. Bradesco will receive 2,378,374,445 new Odontoprev shares in exchange for all BGS shares, based on an exchange ratio of 0.17998067486 Odontoprev share per BGS share. After the transaction, Bradesco will own 91.35% of Odontoprev’s total and voting capital and current Odontoprev shareholders will hold 8.65%, excluding treasury shares and any withdrawal effects. Odontoprev’s dental operations and related assets will be contributed to Mediservice, and Odontoprev/Bradsaúde will act solely as a holding company for Bradesco’s healthcare businesses. The companies highlight expected commercial synergies, broader healthcare scope, and potential Basel ratio benefits for Bradesco, while noting that the spin-off itself does not change Bradesco’s share capital and does not create withdrawal rights for Bradesco or Bradseg shareholders.
Banco Bradesco S.A. responded to a request from the Brazilian securities regulator about media comments on its agribusiness growth targets. The article cited a projection of 15%–20% growth in the direct agribusiness portfolio in 2026, on a base then estimated at R$ 120 billion.
Bradesco explains that these rural credit projections are already included in its previously released guidance, so it did not see a need to publish a separate material fact. The bank emphasizes that these projections are not guarantees of future performance and are subject to risks and uncertainties.
It also cites applicable Brazilian regulations, including Resolution No. 44/2021, and reiterates that any material facts or changes in projections will be disclosed to the market in a timely manner through the appropriate channels.
Banco Bradesco S.A. filed a report summarizing January 2026 share positions and trades by management, their families, treasury, and numerous controlled and related companies. Most groups, including the controlling shareholder group, board of directors, audit committee, technical bodies, treasury, and affiliates, showed no operations in securities or derivatives during the month and unchanged balances.
The only reported trades came from the Board of Executive Officers, which executed sales of non-voting shares totaling 41,869 shares for R$ 771,813.04, plus a securities lending credit of 3,942 non-voting shares for R$ 72,059.76. After these movements, this group held 68,136 common shares and 10,767,054 non-voting shares. The controller group maintained holdings of 3,811,582,439 common shares and 121,067,106 non-voting shares with unchanged participation percentages.
Banco Bradesco is calling special and annual shareholders’ meetings, to be held exclusively digitally on March 10, 2026, to vote on key capital, governance and payout decisions. The board proposes increasing share capital by R$6.67 billion, from R$87.1 billion to R$93.77 billion, through capitalization of the Legal Reserve, without issuing new shares or bringing in fresh cash.
Shareholders will also vote on updating the bylaws to allow profit sharing for management, with the Board of Directors empowered to set amounts within Brazilian legal limits. For 2025, Bradesco reports net income of R$24.55 billion and proposes allocating R$1.06 billion to the Legal Reserve, R$5.67 billion to the Statutory Reserve and R$14.50 billion as interest on shareholders’ equity. Of this payout, R$7.60 billion has already been paid and R$6.90 billion is scheduled for payment in 2026, corresponding to about 61% of adjusted net income and satisfying the 30% mandatory dividend rule.